Morocco medicine price database

HUMIRA

ADALIMUMAB

Public price

7,62 MAD

Active substance

ADALIMUMAB

Laboratory

MAPHAR

What is this medicine?

HADLIMA (adalimumab-bwwd) is a biosimilar to HUMIRA (adalimumab) that acts as a tumor necrosis factor (TNF) blocker.

Verified summary

ADALIMUMAB, SOLUTION INJECTABLE, 40 MG, BOITE DE 2 STYLOS DE 0,8 ML

Common uses

moderately to severely active rheumatoid arthritis,moderately to severely active polyarticular juvenile idiopathic arthritis,active psoriatic arthritis,active ankylosing spondylitis,moderately to severely active Crohn’s disease,moderately to severely active ulcerative colitis,moderate to severe chronic plaque psoriasis,moderate to severe hidradenitis suppurativa,non-infectious intermediate, posterior, and panuveitis

Class

tumor necrosis factor (TNF) blocker

Laboratory

MAPHAR

Hospital price

7,44 MAD

Strength

40 MG

Form

SOLUTION INJECTABLE

Presentation

BOITE DE 2 STYLOS DE 0,8 ML

Commercial status

Non Commercialisé

This information is informational and must be confirmed by a pharmacist or doctor. Do not change medicine or dosage based only on this page.

Price history

Reference price recorded since 2026-06-01: 7,62 MAD

Available presentations and strengths

Medicines with the same active substance